UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/535,084	06/08/2006	Claus Harder	117163.00137	8537
	7590 12/17/200 R & PARKS, LLP	EXAMINER		
One GOJO Plaz		FRAZIER, BARBARA S		
Suite 300 AKRON, OH 4	4311-1076		ART UNIT	PAPER NUMBER
			1611	
			NOTIFICATION DATE	DELIVERY MODE
			12/17/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patents@hahnlaw.com akron-docket@hotmail.com

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/535,084	HARDER ET AL.	
Examiner	Art Unit	

BAI	RBARA FRAZIER	1611	
The MAILING DATE of this communication appears of	on the cover sheet with the	correspondence add	ress
THE REPLY FILED <u>07 December 2009</u> FAILS TO PLACE THIS API	PLICATION IN CONDITION F	OR ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on the sapplication, applicant must timely file one of the following replication in condition for allowance; (2) a Notice of Appeal (was for Continued Examination (RCE) in compliance with 37 CFR 1 periods:	ame day as filing a Notice of es: (1) an amendment, affidav vith appeal fee) in compliance	Appeal. To avoid abar it, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expiresmonths from the mailing date b) The period for reply expires on: (1) the mailing date of this Adviso no event, however, will the statutory period for reply expire later the Examiner Note: If box 1 is checked, check either box (a) or (b). Of MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).	ry Action, or (2) the date set forth an SIX MONTHS from the mailin	g date of the final rejection	n.
Extensions of time may be obtained under 37 CFR 1.136(a). The date on whave been filed is the date for purposes of determining the period of extension under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shorte set forth in (b) above, if checked. Any reply received by the Office later than may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	n and the corresponding amount ned statutory period for reply orig	of the fee. The appropria inally set in the final Office	ate extension fee e action; or (2) as
2. The Notice of Appeal was filed on A brief in compliance filing the Notice of Appeal (37 CFR 41.37(a)), or any extension Notice of Appeal has been filed, any reply must be filed within AMENDMENTS	thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. The proposed amendment(s) filed after a final rejection, but proposed amendment(s) filed after a final rejection, but proposed (a) They raise new issues that would require further consider (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better for appeal; and/or	ration and/or search (see NO	TE below);	
(d) They present additional claims without canceling a corre- NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.116 ar	nd 41.33(a)).		
 4. The amendments are not in compliance with 37 CFR 1.121. S 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) would be allowable allowed 	<u></u> .	,	,
non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a) whow the new or amended claims would be rejected is provided The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 4.7.9 and 12-15. Claim(s) withdrawn from consideration: 1-3.8.10.11 and 16-23.		ll be entered and an ex	xplanation of
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, but before because applicant failed to provide a showing of good and suff was not earlier presented. See 37 CFR 1.116(e). 			
9. The affidavit or other evidence filed after the date of filing a No entered because the affidavit or other evidence failed to overce showing a good and sufficient reasons why it is necessary and	ome <u>all</u> rejections under appe	al and/or appellant fails	s to provide a
10. The affidavit or other evidence is entered. An explanation of t REQUEST FOR RECONSIDERATION/OTHER		•	
 11. The request for reconsideration has been considered but doe <u>See Continuation Sheet.</u> 12. Note the attached Information <i>Disclosure Statement</i>(s). (PTO 		1 condition for allowan	ce because:
13. Other:	, , , , , , , , , , , , , , , , , , ,		
/Ashwin Mehta/ Primary Examiner, Technology Center 1600	/B. F./ Examiner, Art Unit 1611		

Continuation of 3. NOTE: Applicant's amendment of claim 4 from "wherein the formulation is adapted for intravascular liberation" to "wherein the endoprosthesis is adapted to liberate the one or more elements intravascularly" changes the scope of the claims, requiring further consideration and/or search.

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's arguments are not persuasive for overcoming the rejections. In response tp Applicant's arguments regarding the rejection of the claims over 35 USC 112, second paragraph, this rejection is maintained because the amendment has not been entered, for reasons stated above. In respone to arguments regarding Huebliein, it is noted that Hueblein specifically teaches magnesium with one of six preferred compositions, three of which contain rare earths, particularly neodymium as a choice of 4 rare earths (see paragraphs 16-21), and therefore one skilled in the art has reasonable guidance to select magnesium with neodymium. Furthermore, zirconium is one of about 20 choices for the subsidiary constituent with magnesium or iron (paragraphs 13 and 14), and thus it would be within the purview of the skilled artisan to select zirconium with magnesium or iron by routine experimentation. In response to Applicant's arguments regarding Tikhova and ASM, it is noted that Tikhova and ASM are relied upon to show the positive properties of the alloy, which would be considered capable of use as an endoprosthesis based on the teachings of Hueblein.